Celldex Therapeutics Inc. (CLDX)
NASDAQ · Healthcare
Celldex Therapeutics Inc. Shareholder Equity 2020–2025
Celldex Therapeutics Inc. annual shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Celldex Therapeutics Inc. shareholder equity as of December 31, 2025: 527.2M, a 29.43% decrease year-over-year.
- Celldex Therapeutics Inc. shareholder equity for 2025 were 527.2M, a 29.43% decrease from 2024.
- Celldex Therapeutics Inc. shareholder equity for 2024 were 747.0M, a 74.06% increase from 2023.
- Celldex Therapeutics Inc. shareholder equity for 2023 were 429.2M, a 31.57% increase from 2022.
- Celldex Therapeutics Inc. shareholder equity for 2022 were 326.2M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Celldex Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $527 |
| 2024 | $747 |
| 2023 | $429 |
| 2022 | $326 |
| 2021 | $419 |
| 2020 | $209 |
Celldex Therapeutics Inc. Shareholder Equity — FAQ
Celldex Therapeutics Inc. (CLDX) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CLDX's shareholder equity history?
The chart and table above show Celldex Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.